D. Serisier

发表

Clinical measures of disease in adult non-CF bronchiectasis correlate with airway microbiota composition

G. Rogers, C. J. van der Gast, L. Cuthbertson, 2013, Thorax.

Risks of population antimicrobial resistance associated with chronic macrolide use for inflammatory airway diseases.

D. Serisier, 2013, The Lancet. Respiratory medicine.

Bayesian Estimation of Tobramycin Exposure in Patients with Cystic Fibrosis

M. Barras, S. Hennig, D. Serisier, 2016, Antimicrobial Agents and Chemotherapy.

Effect of long-term, low-dose erythromycin on pulmonary exacerbations among patients with non-cystic fibrosis bronchiectasis: the BLESS randomized controlled trial.

M. McGuckin, S. Bowler, R. Lourie, 2013, JAMA.

A novel microbiota stratification system predicts future exacerbations in bronchiectasis.

M. McGuckin, G. Rogers, D. Rivett, 2014, Annals of the American Thoracic Society.

Predominant pathogen competition and core microbiota divergence in chronic airway infection

G. Rogers, C. Gast, D. Serisier, 2014, The ISME Journal.

Randomized controlled trial of nebulized gentamicin in non-cystic fibrosis bronchiectasis...without patient blinding.

S. Bowler, D. Serisier, 2012, American journal of respiratory and critical care medicine.

Long-term, low-dose erythromycin in bronchiectasis subjects with frequent infective exacerbations.

Megan L. Martin, D. Serisier, M. Martín, 2011, Respiratory medicine.

Improvements in Cystic Fibrosis Lung Disease and Airway Inflammation Associated with Etanercept Therapy for Rheumatoid Arthritis: A Case Report

D. Serisier, S. Visser, M. Martín, 2012, Lung.

Daily versus weekly azithromycin in cystic fibrosis patients

S. Bell, C. Wainwright, S. Bowler, 2007, European Respiratory Journal.

Australasian respiratory and emergency physicians do not use the pneumonia severity index in community‐acquired pneumonia

S. Bowler, D. Serisier, Sophie Williams, 2013, Respirology.

Miscellaneous Antibacterial Drugs

L. Burr, D. Serisier, J. Cunningham, 2014 .

Frozen section of pleural biopsies at medical thoracoscopy assists in correctly identifying benign disease

D. Fielding, P. Hopkins, D. Serisier, 2005, Respirology.

Adult Non-Cystic Fibrosis Bronchiectasis Is Characterised by Airway Luminal Th17 Pathway Activation

S. Hasnain, M. McGuckin, G. Rogers, 2015, PloS one.

Inaccurate data in meta-analysis of macrolides by Guang-Ying et al.

D. Serisier, 2014, Pulmonary pharmacology & therapeutics.

Letter to the editor: inaccurate data in meta-analysis of macrolides by Shi et al.

D. Serisier, 2014, Pulmonary pharmacology & therapeutics.

The evidence base for non‐CF bronchiectasis is finally evolving

D. Serisier, 2014, Respirology.

Macrolides for bronchiectasis and chronic obstructive pulmonary disease: should we worry about antimicrobial resistance?

D. Serisier, 2014 .

Respiratory microbiota: addressing clinical questions, informing clinical practice

D. Shaw, G. Rogers, R. Marsh, 2014, Thorax.

Determining Cystic Fibrosis-Affected Lung Microbiology: Comparison of Spontaneous and Serially Induced Sputum Samples by Use of Terminal Restriction Fragment Length Polymorphism Profiling

G. Rogers, C. J. van der Gast, K. Bruce, 2009, Journal of Clinical Microbiology.

Effect of Long-term, Low-Dose Erythromycin on Pulmonary Exacerbations Among Patients With Non-Cystic Fibrosis Bronchiectasis

M. McGuckin, R. Lourie, Megan L. Martin, 2017 .

Effect of albuterol on maximal exercise capacity in cystic fibrosis.

S. Bowler, D. Serisier, A. Coates, 2007, Chest.

Suspected acute exacerbation of idiopathic pulmonary fibrosis associated with interferon alpha therapy for hepatitis C: case report

D. Serisier, Victoria Ling, M. Mortimore, 2013, SpringerPlus.

Antimicrobial susceptibility and synergy studies of cystic fibrosis sputum by direct sputum sensitivity testing

A. Tuck, M. Carroll, D. Serisier, 2012, European Journal of Clinical Microbiology & Infectious Diseases.

Macrorheology of cystic fibrosis, chronic obstructive pulmonary disease & normal sputum

S. Young, J. Shute, M. Carroll, 2009, Respiratory research.

Eradication of pulmonary methicillin-resistant staphylococcus aureus (MRSA) in cystic fibrosis with linezolid.

M. Carroll, D. Serisier, Graeme R. Jones, 2004, Journal of cystic fibrosis : official journal of the European Cystic Fibrosis Society.

Nocardia paucivorans--a cause of disseminated nocardiosis.

C. Gilpin, C. Coulter, J. McCormack, 2007, The Journal of infection.

Characterization of Bacterial Community Diversity in Cystic Fibrosis Lung Infections by Use of 16S Ribosomal DNA Terminal Restriction Fragment Length Polymorphism Profiling

G. Rogers, P. Hockey, K. Bruce, 2004, Journal of Clinical Microbiology.

The Bronchiectasis And Low-Dose Erythromycin Study (BLESS)

M. McGuckin, S. Bowler, R. Lourie, 2012, ATS 2012.

Antimicrobial susceptibility and synergy studies of cystic fibrosis sputum by direct sputum sensitivity testing

A. Tuck, M. Carroll, D. Serisier, 2012, European Journal of Clinical Microbiology & Infectious Diseases.

Safety, Tolerability And Pharmacokinetics Of Novel Liposomal Ciprofloxacin Formulations For Inhalation In Healthy Volunteers And Non-Cystic Bronchiectasis Patients

P. Bruinenberg, D. Cipolla, D. Serisier, 2010, ATS 2010.

Inhaled antibiotics for lower respiratory tract infections: focus on ciprofloxacin.

D. Serisier, 2012, Drugs of today.

M. Carroll, D. Serisier, 2006, Journal of cystic fibrosis : official journal of the European Cystic Fibrosis Society.

Inhaled, dual release liposomal ciprofloxacin in non-cystic fibrosis bronchiectasis (ORBIT-2): a randomised, double-blind, placebo-controlled trial

P. Thompson, D. Bilton, I. Gonda, 2013, Thorax.

The effect of long-term macrolide treatment on respiratory microbiota composition in non-cystic fibrosis bronchiectasis: an analysis from the randomised, double-blind, placebo-controlled BLESS trial.

G. Rogers, K. Bruce, L. Burr, 2014, The Lancet. Respiratory medicine.

Pharmacokinetics and antibacterial activity of inhaled liposomal ciprofloxacin hydrochloride in healthy volunteers and in cystic fibrosis (CF) patients

P. Bruinenberg, D. Cipolla, D. Serisier, 2009 .

Inhaled Liposomal Ciprofloxacin Hydrochloride Significantly Reduces Sputum Pseudomonas Aeruginosa Density in CF and Non-CF Bronchiectasis.

D. Bilton, D. Serisier, J. Blanchard, 2009, ATS 2009.

Alveolar haemorrhage in anti-glomerular basement membrane disease without detectable antibodies by conventional assays

J. Armstrong, D. Serisier, R. Wong, 2006, Thorax.

Diffuse alveolar haemorrhage in a young male smoker: a word of caution

J. Armstrong, D. Serisier, R. Wong, 2006, Internal medicine journal.

Use of 16S rRNA Gene Profiling by Terminal Restriction Fragment Length Polymorphism Analysis To Compare Bacterial Communities in Sputum and Mouthwash Samples from Patients with Cystic Fibrosis

G. Rogers, G. Connett, P. Hockey, 2006, Journal of Clinical Microbiology.

Use of 16 S rRNA Gene Profiling by Terminal Restriction Fragment Length Polymorphism Analysis To Compare Bacterial Communities in Sputum and Mouthwash Samples from Patients with Cystic Fibrosis †

G. Rogers, G. Connett, P. Hockey, 2006 .

Bacterial activity in cystic fibrosis lung infections

G. Rogers, P. Hockey, K. Bruce, 2005, Respiratory research.

Clopidogrel Plus Aspirin Versus Warfarin in Patients With Stroke and Aortic Arch Plaques

D. Blacker, G. Hankey, M. Kaste, 2014, Stroke.

Matrix metalloproteinases vary with airway microbiota composition and lung function in non-cystic fibrosis bronchiectasis.

M. McGuckin, S. Taylor, G. Rogers, 2015, Annals of the American Thoracic Society.

Inhaled heparin in cystic fibrosis

J. Conway, J. Shute, P. Hockey, 2006, European Respiratory Journal.

Effect of a simple educational intervention on the hospital management of community‐acquired pneumonia

S. Bowler, D. Serisier, 2007, Respirology.

Safety, tolerability, pharmacokinetics and antimicrobial activity of inhaled liposomal ciprofloxacin formulations in humans

P. Bruinenberg, D. Cipolla, D. Serisier, 2010 .

Determining Cystic Fibrosis-Affected Lung Microbiology: Comparison of Spontaneous and Serially Induced Sputum Samples by Use of Terminal Restriction Fragment Length Polymorphism Profiling

G. Rogers, C. J. van der Gast, K. Bruce, 2009, Journal of Clinical Microbiology.

Republished: Respiratory microbiota: addressing clinical questions, informing clinical practice

D. Shaw, G. Rogers, R. Marsh, 2014, Postgraduate Medical Journal.